The efficacy and safety profiles of disease activity-guided dose reduction of tumor necrosis factor inhibitors are maintained for up to 3 years in patients with rheumatoid arthritis, follow-up results of the DRESS study suggest.

Results of the ORAL Strategy trial suggest that tofacitinib given in combination with methotrexate, but not alone, is noninferior to adalimumab plus methotrexate for the treatment of patients with rheumatoid arthritis and an inadequate response to methotrexate.

Presentations on the final day of EULAR 2017 examined the relationship between diet, obesity, and rheumatologic diseases.

 Findings from the ARTIS study group suggest that biologic disease-modifying antirheumatic drugs and tumor necrosis factor inhibitors are not associated with an increased overall cancer risk compared with conventional synthetic DMARDs.

Phase II trial results presented at the Annual European Congress of Rheumatology (EULAR) 2017 support the efficacy of two new compounds for the treatment of osteoarthritis (OA).

The addition of high-dose glucocorticoids to first-line adalimumab and methotrexate in the treatment of rheumatoid arthritis fails to further improve efficacy, results of a phase IV study show.